G Iii Apparel Group Ltd /De/
$775.45M- Market cap
- $1.17B
- Debt
- +$11.74M
- Cash
- −$406.66M
Capital structure 99% equity / 1% debt · EV / Revenue 0.26x · EV / EBITDA 5.42x
Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
Decision snapshot: GIII stock price at discount vs ALNY $27.74 current versus $172.46 implied using P/E multiple.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at ALNY's multiple
Implied fair value · at GIII's multiple
Snapshot Sep 4, 4:00 PM ET
Metric by metric
Where each company leads, and how wide the gap is.
Growth lag
Pricing power
Operating leverage
Multiple discount
Value edge
Lower leverage
Statements
Core statements aligned to each company's latest fiscal year.
SEC periods: GIII FY 2026 (ended Jan 31, 2026) · ALNY FY 2025 (ended Dec 31, 2025). Fiscal years are not aligned.
Trendline
Six fiscal years of revenue, earnings, and margins before underwriting a re-rating.
Price framework
Market cap plus debt, less cash.
Capital structure 99% equity / 1% debt · EV / Revenue 0.26x · EV / EBITDA 5.42x
Capital structure 90% equity / 10% debt · EV / Revenue 10.25x · EV / EBITDA 63.81x
ALNY carries the larger enterprise value at $38.07B against $775.45M; GIII trades on the lower EV / Revenue multiple (0.26x vs 10.25x); GIII on the lower EV / EBITDA (5.42x vs 63.81x).
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
G III APPAREL GROUP LTD /DE/ · implied price per share
Bear
$81.16
Base
$93.91
Bull
$110.53
ALNYLAM PHARMACEUTICALS, INC. · implied price per share
At least 3 of the last 5 annual free-cash-flow observations must be positive.
Balance sheet health
Financial health checks to separate durable balance sheets from potential value traps.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Debt / equity
Total debt against shareholders' equity
0.01x
5.22x
Net debt / EBITDA
Leverage against operating earnings
-2.76x
4.13x
Cash and equivalents
Liquid reserves on the balance sheet
$406.66M
$1.66B
Total debt
Interest-bearing obligations outstanding
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
LEVI STRAUSS & CO
GIII vs LEVI
Capri Holdings Ltd
GIII vs CPRI
TAPESTRY, INC.
GIII vs TPR
AMERICAN EAGLE OUTFITTERS INC
GIII vs AEO
Moderna, Inc.
GIII vs MRNA
Sarepta Therapeutics, Inc.
GIII vs SRPT
VERTEX PHARMACEUTICALS INC / MA
GIII vs VRTX
BioNTech SE
GIII vs BNTX
ACADIA PHARMACEUTICALS INC
GIII vs ACAD
$11.74M
$4.12B
LLM-powered synthesis
An on-demand narrative read of the same deterministic data.
The deterministic comparison remains available. Sign in when you want an on-demand narrative synthesis of the same data.